MindWalk CEO to Join Virtual Panel on Drug Discovery
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 12 2026
0mins
Source: Newsfilter
- Executive Participation: MindWalk Holdings CEO Dr. Jennifer Bath will participate in a virtual panel hosted by Jones on June 15, 2026, discussing new opportunities in drug discovery, which is expected to attract significant investor interest.
- Showcasing Technological Edge: MindWalk's HYFT® technology powers ReefIQ™, enhancing the analytical value of biological data by connecting 660 million biological patterns and 25 billion relationships, demonstrating the company's leadership in the bio-AI sector.
- Addressing Industry Challenges: Dr. Bath emphasizes that the biggest challenge in drug discovery is the fragmentation of biological data, and MindWalk's technology aims to solve this issue by integrating biology with computational power, thereby improving drug development efficiency.
- Future Development Outlook: The panel will explore the convergence of high-performance computing and biological knowledge representation, potentially bringing revolutionary changes to drug discovery and further solidifying MindWalk's market position in life sciences.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABSI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABSI
Wall Street analysts forecast ABSI stock price to fall
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 11.110
Low
4.32
Averages
7.66
High
10.00
Current: 11.110
Low
4.32
Averages
7.66
High
10.00
About ABSI
Absci Corporation is a clinical-stage biopharmaceutical company advancing therapeutics with generative design. Its Integrated Drug Creation platform combines artificial intelligence (AI) models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. Its approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Alongside collaborations with pharmaceutical, biotech, tech, and academic companies, the Company is advancing its own pipeline of AI- designed therapeutics. These include ABS-101, an antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, for hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. It has four wholly owned, internally developed programs focusing on cytokine biology. Its other pipeline programs include ABS-301 and ABS-501.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
United Airlines, Corning, and Absci Reach Record Highs Amid Positive Market Trends
- Oil Price Boost for UAL: United Airlines' stock reached a record high of $130.6 as benchmark oil prices fell to their lowest levels since before the Iran conflict, alleviating supply disruption fears and enhancing profit outlook.
- Tech Innovations Drive Growth: The airline launched its first transatlantic flight equipped with SpaceX's Starlink and partnered to offer live TV during flights, reinforcing investor confidence in its long-term strategy.
- Surge in Fiber Network Demand: Corning's stock hit $217.09 as investors focused on the rising demand for optical networking components amid the AI boom, particularly due to a long-term deal with Amazon that is expected to significantly boost product demand.
- Positive Clinical Data for ABS-201: Absci's stock climbed to a four-year high of $11 after promising results for its hair-loss treatment ABS-201 and completing a $100 million public offering, attracting several prominent investors.
See More
Absci Corporation Reports Significant Clinical Trial Progress
- Clinical Trial Progress: Absci's experimental drug ABS-201 demonstrated good tolerability in healthy volunteers with no serious side effects, and testing on actual pattern hair loss patients is expected to begin in the second half of 2026, further validating its efficacy.
- Funding Plan: To support the development of ABS-201 for both hair loss and endometriosis, Absci priced an offering of approximately 13.5 million shares at $7.41 each, aiming to raise about $100 million, with proceeds primarily allocated for clinical research and corporate needs.
- Positive Market Reaction: Following the announcement of encouraging clinical trial results, Absci's stock surged 36% on Wednesday, potentially marking its best single-day performance ever, reflecting strong investor confidence in the drug's market potential.
- Optimistic Analyst Ratings: Among the 11 analysts covering ABSI, 10 rated it as 'Buy' or higher, with a 12-month price target of $9.61, indicating a potential upside of 30% from Tuesday's close, showcasing a positive outlook on its future performance.
See More
Sprott Silver Miners ETF Underperforms
- ETF Performance: The Sprott Silver Miners & Physical Silver ETF is down approximately 5.2% in Wednesday afternoon trading, indicating a weak sentiment towards silver-related assets that may impact investor confidence.
- Weak Individual Stocks: Among the ETF's components, Americas Gold and Silver fell about 8.3%, while Hycroft Mining Holding dropped approximately 8.2%, reflecting operational challenges and market pressures faced by these companies.
- Market Sentiment Impact: The decline in the silver mining ETF may be linked to a broader market decrease in safe-haven demand for precious metals, leading investors to shift towards other asset classes, which could affect silver price stability.
- Investor Focus: As silver prices become more volatile, investors should monitor the financial health of related companies and market trends to make more informed investment decisions.
See More
NASDAQ 100 Pre-Market Activity Overview
- Market Performance: The NASDAQ 100 Pre-Market Indicator rose by 160.39 points to 29,507.66, reflecting investor optimism that could drive positive performance in upcoming trading sessions.
- Active Stocks: Wendy's Company (WEN) increased by $1.4644 in pre-market trading with a volume of 18,113,633 shares, currently priced at $7.72, which is 96.49% of its target price of $8, indicating strong buying interest.
- Short Interest Rates: Absci Corporation (ABSI) and Sunrun Inc. (RUN) have short interest days of 7.48 and 7.90 respectively, suggesting high demand for these stocks that may influence their future price movements.
- Target Price Analysis: Novartis AG (NVS) is currently priced at $153.51, exceeding its target price of $142 by 108.11%, demonstrating market confidence in its future growth and potentially attracting more investor attention.
See More
Absci Shares Surge 20% After $100M Financing Announcement
- Significant Financing: Absci announced a $100 million financing from Eli Lilly and several private equity firms, resulting in a roughly 20% surge in premarket trading, indicating strong market confidence in its financing capabilities.
- Stock Offering Pricing: The company priced an underwritten offering of 13,495,277 shares at $7.41 each, with proceeds aimed at supporting the development of its anti-PRLR antibody ABS-201 for androgenetic alopecia and endometriosis, showcasing its strategic positioning in the biopharma sector.
- Diverse Investor Background: The financing includes participation from private equity investors such as Adage, BVF Partners, Columbia Threadneedle, Invus, and Redmile, reflecting market confidence in Absci's growth potential and potentially enhancing its appeal in capital markets.
- Clear Use of Funds: Proceeds will be allocated to support the development of ABS-201 and general working capital, indicating the company's strategic decisions to drive innovative drug development and maintain operations, aiming to enhance its competitive position in the market.
See More
Absci Shares Surge 21% on Positive Hair Loss Therapy Trial Data and $100M Offering
- Clinical Trial Progress: Absci (ABSI) reported interim results from its early-stage trial of hair loss therapy ABS-201 as of June 8, 2026, indicating that 32 participants across four single ascending dose groups tolerated the treatment well, with no serious adverse events, highlighting the therapy's safety and potential efficacy.
- Funding Initiative: The company concurrently announced an underwritten offering of approximately 13.5 million shares at $7.41 per share, aiming to raise about $100 million, which will be utilized to further advance ABS-201 for androgenetic alopecia and for other corporate purposes, demonstrating confidence in the project.
- Positive Market Reaction: Following the trial data release, Absci's shares surged approximately 21% in premarket trading, reflecting investor optimism regarding the new therapy and expectations for the company's future growth.
- Future Outlook: Absci is on track to report interim proof-of-concept data and full proof-of-concept data in H2 2026 and early 2027, respectively, indicating a long-term strategic commitment to the hair loss treatment market.
See More
United Airlines, Corning, and Absci Reach Record Highs Amid Positive Market Trends
- Oil Price Boost for UAL: United Airlines' stock reached a record high of $130.6 as benchmark oil prices fell to their lowest levels since before the Iran conflict, alleviating supply disruption fears and enhancing profit outlook.
- Tech Innovations Drive Growth: The airline launched its first transatlantic flight equipped with SpaceX's Starlink and partnered to offer live TV during flights, reinforcing investor confidence in its long-term strategy.
- Surge in Fiber Network Demand: Corning's stock hit $217.09 as investors focused on the rising demand for optical networking components amid the AI boom, particularly due to a long-term deal with Amazon that is expected to significantly boost product demand.
- Positive Clinical Data for ABS-201: Absci's stock climbed to a four-year high of $11 after promising results for its hair-loss treatment ABS-201 and completing a $100 million public offering, attracting several prominent investors.
See More
Absci Corporation Reports Significant Clinical Trial Progress
- Clinical Trial Progress: Absci's experimental drug ABS-201 demonstrated good tolerability in healthy volunteers with no serious side effects, and testing on actual pattern hair loss patients is expected to begin in the second half of 2026, further validating its efficacy.
- Funding Plan: To support the development of ABS-201 for both hair loss and endometriosis, Absci priced an offering of approximately 13.5 million shares at $7.41 each, aiming to raise about $100 million, with proceeds primarily allocated for clinical research and corporate needs.
- Positive Market Reaction: Following the announcement of encouraging clinical trial results, Absci's stock surged 36% on Wednesday, potentially marking its best single-day performance ever, reflecting strong investor confidence in the drug's market potential.
- Optimistic Analyst Ratings: Among the 11 analysts covering ABSI, 10 rated it as 'Buy' or higher, with a 12-month price target of $9.61, indicating a potential upside of 30% from Tuesday's close, showcasing a positive outlook on its future performance.
See More
Sprott Silver Miners ETF Underperforms
- ETF Performance: The Sprott Silver Miners & Physical Silver ETF is down approximately 5.2% in Wednesday afternoon trading, indicating a weak sentiment towards silver-related assets that may impact investor confidence.
- Weak Individual Stocks: Among the ETF's components, Americas Gold and Silver fell about 8.3%, while Hycroft Mining Holding dropped approximately 8.2%, reflecting operational challenges and market pressures faced by these companies.
- Market Sentiment Impact: The decline in the silver mining ETF may be linked to a broader market decrease in safe-haven demand for precious metals, leading investors to shift towards other asset classes, which could affect silver price stability.
- Investor Focus: As silver prices become more volatile, investors should monitor the financial health of related companies and market trends to make more informed investment decisions.
See More
NASDAQ 100 Pre-Market Activity Overview
- Market Performance: The NASDAQ 100 Pre-Market Indicator rose by 160.39 points to 29,507.66, reflecting investor optimism that could drive positive performance in upcoming trading sessions.
- Active Stocks: Wendy's Company (WEN) increased by $1.4644 in pre-market trading with a volume of 18,113,633 shares, currently priced at $7.72, which is 96.49% of its target price of $8, indicating strong buying interest.
- Short Interest Rates: Absci Corporation (ABSI) and Sunrun Inc. (RUN) have short interest days of 7.48 and 7.90 respectively, suggesting high demand for these stocks that may influence their future price movements.
- Target Price Analysis: Novartis AG (NVS) is currently priced at $153.51, exceeding its target price of $142 by 108.11%, demonstrating market confidence in its future growth and potentially attracting more investor attention.
See More
Absci Shares Surge 20% After $100M Financing Announcement
- Significant Financing: Absci announced a $100 million financing from Eli Lilly and several private equity firms, resulting in a roughly 20% surge in premarket trading, indicating strong market confidence in its financing capabilities.
- Stock Offering Pricing: The company priced an underwritten offering of 13,495,277 shares at $7.41 each, with proceeds aimed at supporting the development of its anti-PRLR antibody ABS-201 for androgenetic alopecia and endometriosis, showcasing its strategic positioning in the biopharma sector.
- Diverse Investor Background: The financing includes participation from private equity investors such as Adage, BVF Partners, Columbia Threadneedle, Invus, and Redmile, reflecting market confidence in Absci's growth potential and potentially enhancing its appeal in capital markets.
- Clear Use of Funds: Proceeds will be allocated to support the development of ABS-201 and general working capital, indicating the company's strategic decisions to drive innovative drug development and maintain operations, aiming to enhance its competitive position in the market.
See More
Absci Shares Surge 21% on Positive Hair Loss Therapy Trial Data and $100M Offering
- Clinical Trial Progress: Absci (ABSI) reported interim results from its early-stage trial of hair loss therapy ABS-201 as of June 8, 2026, indicating that 32 participants across four single ascending dose groups tolerated the treatment well, with no serious adverse events, highlighting the therapy's safety and potential efficacy.
- Funding Initiative: The company concurrently announced an underwritten offering of approximately 13.5 million shares at $7.41 per share, aiming to raise about $100 million, which will be utilized to further advance ABS-201 for androgenetic alopecia and for other corporate purposes, demonstrating confidence in the project.
- Positive Market Reaction: Following the trial data release, Absci's shares surged approximately 21% in premarket trading, reflecting investor optimism regarding the new therapy and expectations for the company's future growth.
- Future Outlook: Absci is on track to report interim proof-of-concept data and full proof-of-concept data in H2 2026 and early 2027, respectively, indicating a long-term strategic commitment to the hair loss treatment market.
See More
